https://www.marketscreener.com/quote/stock/TRAVERE-THERAPEUTICS-INC-15458731/news/Retrophin-Initiates-Pivotal-Phase-3-Clinical-Trial-of-Sparsentan-for-the-Treatment-of-Focal-Segmenta-26271800/?utm_source=telegram&utm_medium=social&utm_campaign=share